A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia

NCT00463606 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

760

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia
Dyslipidemia

Interventions

DRUG: ABT-335 and rosuvastatin calcium
DRUG: ABT-335
DRUG: rosuvastatin calcium

Sponsor

AstraZeneca